Skip directly to content

Afrique Moyen-Orient Étude épidémiologique cardiovasculaire (ECA) - Facteurs de risque

 

High burden of cardiovascular risk factors in Africa Middle East region1-3

 

Cardiovascular (CV) disease is the leading cause of death worldwide, and 80% of global CV deaths occur in developing countries.1 Early detection and control of risk factors are essential in the prevention of CV disease.

 

There is limited data on the burden of CV risk factors in the Africa and Middle East (AfME) region. The Africa Middle East Cardiovascular Epidemiological (ACE)3 study was a cross-sectional epidemiology study, which evaluated the presence of CV risk factors such as dyslipidaemia, hypertension, obesity, smoking, and diabetes mellitus in 4,378 patients from general practice/outpatient clinics of 14 countries in the Africa Middle East region.2
 
Please click video to find out further details of the ACE study.
 
 

The study reported a significant burden of CV risk in the region. For every 10 patients screened, 9 had at least one modifiable CV risk factor. The risk factors were present in a large proportion of younger patients, which is a cause for concern. Populations living in urban regions were at more risk than those from rural regions. In addition, many patients who had pre-existing hypertension or dyslipidaemia were found to have uncontrolled disease.2

 
These findings highlight the need for screening of CV risk factors to facilitate early identification and management of CV diseases.2

 

For more information on the study results, please select the below sections.

 

 

References: 
  1. Cardiovascular diseases (CVDs). WHO fact sheet N°317. Available at http://www.who.int/mediacentre/factsheets/fs317/en/ Updated January 2015. Accessed March 3, 2015.
  2. Alsheikh Ali AA, Omar MI, Raal FJ, et al. Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study. PLoS One. 2014;9(8):e102830.
  3. The Africa Middle East Cardiovascular Epidemiological (ACE) study was funded by Pfizer

 

Pfizer Identification Number: WGFLIP1215092